Mazdutide (100 mg Vial) Dosage Protocol
Mazdutide is a dual GLP-1 / glucagon receptor agonist studied for obesity and type-2 diabetes. Phase 2 trials report substantial weight loss with the dual mechanism distinct from GLP-1/GIP agonists.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: Once weekly | Half-life: ~6 days
Standard Approach (3 mL = 33.33 mg/mL)
Reconstituting with 3 mL bacteriostatic water produces a concentration of 33.33 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Weeks 1–4 (titration) | 2.5 mg | 7.5 units | 0.075 mL | 40 doses |
| Weeks 5–8+ (target) | 5 mg | 15 units | 0.15 mL | 20 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 5 mg per dose, once weekly (1 dose/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| Mazdutide (100 mg) vials | 1 vials | 1 vials |
| Insulin syringes (U-100) | 8 | 12 |
| Bacteriostatic water (10 mL) | 1 × 10 mL | 1 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
Mazdutide pairs GLP-1 and glucagon receptor activation, producing weight loss via both appetite suppression (GLP-1) and increased energy expenditure (glucagon). The mechanism is distinct from tirzepatide (GLP-1/GIP) and may suit users who plateau on GIP-containing compounds.
Phase 2 protocols ran 24 weeks at the 6 mg maintenance dose with 12–15% mean weight loss.
Dosing Protocol
Standard 4-week titration:
- Weeks 1–4: 1.5 mg once weekly.
- Weeks 5–8: 3.0 mg once weekly.
- Weeks 9–12: 4.5 mg once weekly.
- Weeks 13+ (maintenance): 6.0 mg once weekly.
Energy-expenditure note: Glucagon activation increases resting metabolic rate. Some users notice increased thirst and mild heart-rate elevation as expected effects.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
Mazdutide is an oxyntomodulin analog activating both GLP-1 and glucagon receptors. GLP-1 activation provides appetite suppression and improved glucose handling; glucagon activation increases energy expenditure. The combination produces weight loss with a mechanism complementary to GLP-1/GIP dual agonists.
Potential Benefits & Side Effects
Potential Benefits
- Phase 2 obesity: ~12–15% weight reduction at 6 mg weekly.
- Improvements in HbA1c in type-2 diabetes trials.
- Reductions in liver fat content reported.
- Once-weekly dosing.
Side Effect Profile
- Nausea, vomiting, diarrhea (typical incretin GI profile).
- Decreased appetite.
- Injection-site reactions.
Lifestyle Factors
- Hydration, protein intake, resistance training — standard incretin protocol.
- Smaller meals, slow titration to manage GI burden.
Injection Technique
- Subcutaneous, abdomen/thigh/upper arm. Rotate weekly.
- Room-temp solution, 90° angle.